Kramer Levin Names Amy Caton Co-Chair of the Firm’s Bankruptcy and Restructuring Practice

Kramer Levin is pleased to announce the promotion of Amy Caton to co-chair of the firm’s Bankruptcy and Restructuring practice. Amy will co-lead the group along with current co-chair Kenneth H. Eckstein. Thomas Moers Mayer will step down from his co-chair position and will continue as a senior partner in Kramer Levin’s Bankruptcy and Restructuring department.

For the past 25 years, Amy has represented investors, groups and creditors’ committees in many of the nation’s most complex and highest-profile restructurings, including Puerto Rico, PREPA (Puerto Rico Electric and Power Authority), Hertz, Brazos Electric, PG&E, AES PR, Purple Line, American Airlines and General Motors.

Amy has received many accolades for her accomplishments, with American Lawyer naming her a “Dealmaker of the Year” and Turnarounds & Workouts naming her three times in its short list of “Restructuring Lawyers of the Year.” Amy is a Class of 2024 member of the American College of Bankruptcy and member of the Society of Municipal Analysts. She is also a member of Kramer Levin’s Executive Committee, where she has served since her election in 2015.

Amy's appointment is one of many developments within the bankruptcy practice, which has long been considered one of the best in the nation. Kramer Levin appointed Bankruptcy and Restructuring partner Adam Rogoff to co-lead the firm’s multidisciplinary health care industry group in 2023. Last year, the firm also hired lateral partners Alexander Woolverton and Scott Welkis, who co-lead the firm’s Special Situations practice. In 2022, Kramer Levin combined with DC litigation and appellate boutique Robbins, Russell, Englert, Orseck & Untereiner LLP, adding to the enormous depth of litigation talent on the bankruptcy team.

In the past few months, Kramer Levin has been selected as counsel for the unsecured creditors’ committee of Rite Aid Corp. and the unsecured creditors’ committee of Genesis Care, as well as for holders of $400 million of Fulcrum bonds and holders of $350 million of Enviva bonds. The firm was also selected as counsel for the unsecured creditors’ committee of Endo Pharmaceuticals last year.